TY - JOUR
T1 - Comprehensive review into the challenges of gastrointestinal tumors in the gulf and levant countries
AU - Farhat, Fadi
AU - Farsi, Abdulaziz Al
AU - Mohieldin, Ahmed
AU - Bahrani, Bassim Al
AU - Sbaity, Eman
AU - Jaffar, Hassan
AU - Kattan, Joseph
AU - Rasul, Kakil
AU - Saad, Khairallah
AU - Assi, Tarek
AU - Morsi, Waleed El
AU - Abood, Rafid A.
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Although gastrointestinal stromal tumors (GISTs) are rare, with an incidence of 1/100000 per year, they are the most common sarcomas in the peritoneal cavity. Despite considerable progress in the diagnosis and treatment of GIST, about half of all patients are estimated to experience recurrence. With only two drugs, sunitinib and regorafenib, approved by the Food and Drug Administration, selecting treatment options after imatinib failure and coordinating multidisciplinary care remain challenging. In addition, physicians across the Middle East face some additional and unique challenges such as lack of published local data from clinical trials, national disease registries and regional scientific research, limited access to treatment, lack of standardization of care, and limited access to mutational analysis. Although global guidelines set a framework for the management of GIST, there are no standard local guidelines to guide clinical practice in a resource-limited environment. Therefore, a group of 11 experienced medical oncologists from across the Gulf and Levant region, part of the Rare Tumors Gastrointestinal Group, met over a period of one year to conduct a narrative review of the management of GIST and to describe regional challenges and gaps in patient management as an essential step to proposing local clinical practice recommendations.
AB - Although gastrointestinal stromal tumors (GISTs) are rare, with an incidence of 1/100000 per year, they are the most common sarcomas in the peritoneal cavity. Despite considerable progress in the diagnosis and treatment of GIST, about half of all patients are estimated to experience recurrence. With only two drugs, sunitinib and regorafenib, approved by the Food and Drug Administration, selecting treatment options after imatinib failure and coordinating multidisciplinary care remain challenging. In addition, physicians across the Middle East face some additional and unique challenges such as lack of published local data from clinical trials, national disease registries and regional scientific research, limited access to treatment, lack of standardization of care, and limited access to mutational analysis. Although global guidelines set a framework for the management of GIST, there are no standard local guidelines to guide clinical practice in a resource-limited environment. Therefore, a group of 11 experienced medical oncologists from across the Gulf and Levant region, part of the Rare Tumors Gastrointestinal Group, met over a period of one year to conduct a narrative review of the management of GIST and to describe regional challenges and gaps in patient management as an essential step to proposing local clinical practice recommendations.
KW - Challenges
KW - Diagnosis
KW - Disease management
KW - Gastrointestinal stromal tumors
KW - Middle east
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85079788724&partnerID=8YFLogxK
U2 - 10.12998/wjcc.v8.i3.487
DO - 10.12998/wjcc.v8.i3.487
M3 - Review article
AN - SCOPUS:85079788724
SN - 2307-8960
VL - 8
SP - 487
EP - 503
JO - World Journal of Clinical Cases
JF - World Journal of Clinical Cases
IS - 3
ER -